75351
document
Antihypertensive efficacy of cetamolol : a dose-titrated study . This double-blind , placebo-controlled , randomized multicenter study evaluated the antihypertensive efficacy and safety of cetamolol hydrochloride in 108 patients diagnosed as having mild to moderate hypertension . After a placebo lead-in period , patients received either cetamolol 5-10-15 mg/d ( low dose ) , cetamolol 15-25-50 mg/d ( high dose ) , or placebo , once daily for four weeks . Patients began at the lowest dose and were titrated to higher doses based on the first two assessments of diastolic blood pressure and heart rate , which were conducted each week after double-blind treatment was dispensed . After four weeks of treatment 82.4 % , 81.3 % , and 93.3 % of the low-dose group , high-dose group , and placebo group , respectively , were titrated to the maximum dose level . After four weeks of treatment and 24 hours since the patient 's last dose , both cetamolol groups showed a significantly greater ( P less than or equal to .05 ) reduction in supine systolic/diastolic blood pressure ( -18.1 +/- 2.3/-9.2 +/- 1.5 mm Hg [ low dose ] and -17.3 +/- 2.3/-8.3 +/- 1.6 mm Hg [ high dose ] ) than the placebo group ( -9.9 +/- 2.5/-3.5 +/- 1.7 mm Hg ) . In general , the changes in standing ( stabilized ) systolic and diastolic blood pressure were similar to those seen in supine measurements . Significantly more patients receiving cetamolol than those receiving placebo showed a " good response " ( a decrease in diastolic blood pressure of 10 mm Hg or more or measuring less than 90 mm Hg with a decrease of at least 4 mm Hg ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
75352
Intervention_Pharmacological
cetamolol
75353
Intervention_Control
placebo-controlled
75354
Intervention_Pharmacological
cetamolol hydrochloride
75355
Intervention_Control
placebo
75356
Intervention_Pharmacological
cetamolol
75357
Intervention_Pharmacological
cetamolol
75358
Intervention_Control
placebo
75359
Intervention_Control
placebo
75360
Intervention_Pharmacological
cetamolol
75361
Outcome_Other
Antihypertensive efficacy
75362
Outcome_Other
antihypertensive efficacy and safety
75363
Outcome_Physical
diastolic blood pressure
75364
Outcome_Physical
heart rate
75365
Outcome_Physical
supine systolic/diastolic blood pressure
75366
Outcome_Physical
changes in standing ( stabilized ) systolic and diastolic blood pressure